Ovarian Function Insufficiency
Conditions
Brief summary
Ovarian cryopreservation is one of the available option for preserving fertility prior to potentially sterilizing treatments. In the absence of other techniques such as in vitro folliculogenesis or injection of isolated ovarian follicles, this tissue can only be re-used by autograft. In France, the first live birth after orthotopic ovarian transplantation, was obtained by Roux et al. in 2009. This clinical trial aims to collect data on the efficiency of the graft in terms of restoration of ovarian function and live births. It will also allow us to carry out the patient follow-up after ovarian tissue cryopreservation and after autograft when achieved. In cases of neoplastic malignancies, minimal residual disease detection will be performed on ovarian tissue, to avoid any risk of cancer re-seeding.
Interventions
PROCEDUREAutograft of cryopreserved ovarian tissue
Orthotopic transplantation
Sponsors
CHU de Reims
University Hospital, Marseille
Nantes University Hospital
University Hospital, Lille
Central Hospital, Nancy, France
University Hospital, Toulouse
University Hospital, Grenoble
University Hospital, Bordeaux
CMCO SIHCUS, Schiltingheim
University Hospital, Rouen
University Hospital, Limoges
University Hospital, Angers
Centre Hospitalier Universitaire de Nice
Tenon Hospital, Paris
Poissy-Saint Germain Hospital
Hôpital Jean Verdier
University Hospital, Clermont-Ferrand
Hopital Antoine Beclere
Centre Hospitalier Universitaire de Besancon
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 43 Years
Healthy volunteers
No
Inclusion criteria
* Patients who underwent Ovarian tissue cryopreservation * Premature ovarian failure * Patients cured of their primary disease * Women between 18 and 43 years of age * Patients who have already benefited from ovarian tissue autograft
Exclusion criteria
* Patients under trusteeship * Patients placed in receivers * Patients under the protection of a conservator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Restoration of ovarian function by using autograft | 2 years |
Secondary
| Measure | Time frame |
|---|---|
| Number of live births after ovarian tissue autograft | 5 years |
| Number of complications that could result from a surgery with anesthesia or depending on graft quality | 5 years |
| Number of graft recovery | 5 years |
| Number of residual disease development. | 5 years |
Countries
France
Contacts
Primary ContactClotilde AMIOT, MD PhD
Outcome results
None listed